Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


title = "Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts",
abstract = "Purpose: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer{\textquoteright}s Disease (AD) Research Framework derived from [18F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated Tau-181 (PTau181). Methods: We included 351 subjects with varying clinical diagnoses from three cohorts with available FTP PET and CSF PTau181 within 18 months. T-status was derived from (1) FTP visual assessment by two blinded raters; (2) FTP standardized uptake value ratio (SUVR) quantification from a temporal meta-ROI (threshold: SUVR ≥1.27); and (3) Elecsys{\textregistered} Phospho-Tau (181P) CSF (Roche Diagnostics) concentrations (threshold: PTau181 ≥ 24.5 pg/mL). Results: FTP visual reads yielded the highest rates of T+, while T+ by SUVR increased progressively from cognitively normal (CN) through mild cognitive impairment (MCI) and AD dementia. T+ designation by CSF PTau181 was intermediate between FTP visual reads and SUVR values in CN, similar to SUVR in MCI, and lower in AD dementia. Concordance in T-status between modality pairs ranged from 68 to 76% and varied by clinical diagnosis, being highest in patients with AD dementia. In discriminating Aβ + MCI and AD subjects from healthy controls and non-AD participants, FTP visual assessment was most sensitive (0.96) but least specific (0.60). Specificity was highest with FTP SUVR (0.91) with sensitivity of 0.89. Sensitivity (0.73) and specificity (0.72) were balanced for PTau181. Conclusion: The choice of tau biomarker may differ by disease stage and research goals that seek to maximize sensitivity or specificity. Visual interpretations of tau PET enhance sensitivity compared to quantification alone, particularly in early disease stages.",
keywords = "Alzheimer{\textquoteright}s disease, Biomarkers, CSF, Flortaucipir, PET, Tau",
author = "Karine Provost and Leonardo Iaccarino and Soleimani-Meigooni, {David N.} and Suzanne Baker and Lauren Edwards and Udo Eichenlaub and Oskar Hansson and William Jagust and Mustafa Janabi and {La Joie}, Renaud and Orit Lesman-Segev and Mellinger, {Taylor J.} and Miller, {Bruce L.} and Rik Ossenkoppele and Julie Pham and Ruben Smith and Ida Sonni and Amelia Strom and Niklas Mattsson-Carlgren and Rabinovici, {Gil D.} and {Alzheimer{\textquoteright}S Disease Neuroimaging Initiative (Adni)}",
year = "2021",
month = jan,
day = "4",
doi = "10.1007/s00259-020-05152-8",
language = "English",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",